Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Blinklab Limited ( (AU:BB1) ) just unveiled an update.
BlinkLab Limited has announced the expansion of its U.S. clinical trial network by engaging the University of Nebraska Medical Center (UNMC) as a key site for the main phase of its FDA 510(k) diagnostic trial for BlinkLab Dx 1, a digital tool for early autism detection. This strategic move aims to enhance the trial’s geographic diversity and accelerate recruitment, with plans to involve up to ten sites across the U.S. The expansion supports BlinkLab’s strategy for regulatory clearance and long-term clinical adoption, with the main phase set to enroll an additional 750–900 children. The company anticipates submitting its final FDA application in 2026.
More about Blinklab Limited
BlinkLab Limited, founded by neuroscientists at Princeton University, specializes in developing smartphone-based diagnostic platforms for neurodevelopmental conditions such as autism, ADHD, and schizophrenia. Their flagship product is an autism diagnostic test that utilizes AI and machine learning to screen children as young as 18 months, significantly advancing early intervention opportunities.
Average Trading Volume: 277,131
Technical Sentiment Signal: Strong Buy
See more insights into BB1 stock on TipRanks’ Stock Analysis page.